Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)
Trial details
- Registry ID
- NCT01311674
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Engerix-B
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)NCT01311674 | Emergent BioSolutions | Phase 3 | Terminated | 2011-03-11Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |